Expansion & Capabilities Pace Analytical has a nationwide network of laboratories, service centers, and satellite operations plus recent investments in two life sciences laboratories and a new testing method for ultrashort-chain PFAS, signaling expanded capacity and capabilities to support pharmaceutical, biopharmaceutical, and environmental testing projects.

Strategic Partnerships Recent partnerships and collaborations, including Aspire Biolabs for drug-excipient compatibility and formulation development, position Pace as a preferred testing and development partner for complex pharmaceutical programs requiring analytical support across development and manufacturing stages.

Regulatory & Awards The Environmental Business Journal Award for adding Respirable Crystalline Silica testing reinforces Pace’s credibility with regulatory bodies and customers seeking compliant, quality-focused environmental and occupational health testing programs.

Senior Leadership Signals Appointments of a new Chief Executive Officer and a Director of Research & Development in early 2026 indicate a strategic focus on leadership-driven growth, R&D intensity, and enhanced client solutions for advanced testing needs.

Market Positioning With a revenue range of 100M to 250M, a 40-year track record, and a broad client base across industry, consulting, engineering, and government, Pace is well-positioned to pursue larger-scale testing engagements, ongoing PFAS and silica programs, and integrated lab services for regulated sectors.